References
- Drolsum L, Haaskjold E. Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg 1995;21(1):59–63.
- Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309–317.
- Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009;29:46–51.
- Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80–86.
- Bradford JD, Wilkinson CP, Bradford RH. Cystoid macular edema following extracapsular cataract extraction and posterior chamber intraocular lens implantation. Retina 1988;8(3):161–164.
- Jaissle GB, Szurman P, Bartz-Schmidt KU. Recommendation for the implementation of intravitreal injections–statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monbl Augenheilkd 2005;222(5):390–395.
- Conway ME, Canakis C, Livir-Rallatos C, Peyman G. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29:27–33.
- Konstantopoulos A, Williams CP, Luff AJ. Outcome of intravitreal triamcinolone acetonide in postoperative cystoid macular oedema. Eye (Lond) 2008;22(2):219–222.
- Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, et al. Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147(6):1048–1054, 1054.
- Scaramuzzi M, Querques G, Spina C, Lattanzio R, Bandello F. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina 2015;35(6):1216–1222.
- Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Ozurdex Geneva Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453–2460.
- Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, et al. Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica 2013;229(1):21–25.
- Dang Y, Mu Y, Li L, Mu Y, Liu S, Zhang C, et al. Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients. Drug Des Devel Ther 2014;8:1441–1449.
- Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005;25:556–560.
- Armaly ME. Statistical attributes of the steroid hypertensive response in the clinically normal eye, I: the demonstration of three levels of response. Invest Ophthalmol 1965;4:187–197.
- Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;4:198–205.